Xlife Sciences AGXSWX:XLS -11.06%50 Quick Ratio is 0.10 as of Dec. 2025, which is 94% below its 10-year median of 1.57. GuruFocus rates XSWX:XLS with a GF Score™ of 50/100 and a GF Value™ of CHF7.30 (Significantly Overvalued). The stock has 13 warning signs investors should review. Among 1,417 Biotechnology companies, Xlife Sciences AG ranks worse than 96.82% on this metric.
Xlife Sciences AG has a quick ratio of 0.10. It indicates that the company cannot currently fully pay back its current liabilities.
The historical rank and industry rank for Xlife Sciences AG's Quick Ratio or its related term are showing as below:
XSWX:XLS'
s Quick Ratio Range Over the Past 10 Years
Min: 0.1 Med: 1.57 Max: 9.49
Current: 0.1
During the past 8 years, Xlife Sciences AG's highest Quick Ratio was 9.49. The lowest was 0.10. And the median was 1.57.
XSWX:XLS's Quick Ratio is ranked worse than 96.82% of 1417
companies
in the Biotechnology industry
Industry Median: 3.6
vs XSWX:XLS: 0.10
Xlife Sciences AG (XSWX:XLS) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Xlife Sciences AG Quick Ratio Related Terms
Xlife Sciences AG Quick Ratio Historical Data
* Premium members only.
The historical data trend for Xlife Sciences AG's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:XLS vs VRTX, REGN, ALNY: Quick Ratio Comparison
For the Biotechnology subindustry, Xlife Sciences AG's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xlife Sciences AG Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xlife Sciences AG's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Xlife Sciences AG's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Xlife Sciences AG's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xlife Sciences AG (XSWX:XLS) has a Quick Ratio of 0.10 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Xlife Sciences AG and its competitors. This is 94% below median its historical median of 1.57. Over the past decade, Xlife Sciences AG's Quick Ratio has ranged from 0.10 to 9.49. According to the industry distribution chart, Xlife Sciences AG ranks #1372 out of 1417 companies in the Biotechnology industry, placing it in the top 96.8%.
Is Xlife Sciences AG's Quick Ratio too high?
Xlife Sciences AG's current Quick Ratio of 0.10 is 94% below median its 10-year median of 1.57. Over the past 10 years, this metric has ranged from a low of 0.10 to a high of 9.49. The Biotechnology industry median Quick Ratio is 3.60. Xlife Sciences AG's value of 0.10 is 97.2% below this industry median. Based on the distribution chart, Xlife Sciences AG ranks #1372 out of 1417 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Xlife Sciences AG has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xlife Sciences AG's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Xlife Sciences AG ranks #1372 out of 1417 companies for Quick Ratio. This places Xlife Sciences AG in the lower half of its industry. The industry median Quick Ratio is 3.60. Xlife Sciences AG's value of 0.10 is 97.2% below this benchmark. Historically, Xlife Sciences AG's own Quick Ratio has ranged from 0.10 to 9.49 over the past decade. While the company's 10-year median is 1.57 vs. the industry median of 3.60, Xlife Sciences AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xlife Sciences AG's current Quick Ratio of 0.10 is 97.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Xlife Sciences AG and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xlife Sciences AG's current Quick Ratio is 0.10, which is 94% below median its own 10-year median of 1.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xlife Sciences AG stock overvalued right now?
Based on GuruFocus' analysis, Xlife Sciences AG (XSWX:XLS) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF7.30, compared to a current price of CHF20.90 — trading 186.3% above its estimated fair value. The current Quick Ratio is 0.10, which is 94% below median its 10-year median of 1.57 and 97.2% below the Biotechnology industry median of 3.60. Xlife Sciences AG's overall GF Score™ is 50/100 with 13 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Xlife Sciences AG (XSWX:XLS), the current Quick Ratio is 0.10 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xlife Sciences AG (XSWX:XLS) Overvalued in 2026?
Based on GuruFocus' analysis, Xlife Sciences AG stock appears to be overvalued.
The current stock price of CHF20.90 is trading 186.3% above its estimated GF Value™ of CHF7.30.
GuruFocus considers Xlife Sciences AG to be Significantly Overvalued.
Key valuation signals for XSWX:XLS:
Quick Ratio: 0.10 (94% below median its 10-year median of 1.57)
GF Value™: CHF7.30 vs. price of CHF20.90 (186.3% above fair value)
Industry Position: 97.2% below the Biotechnology median (#1372 of 1417)
No single metric tells the full story. See the XSWX:XLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high-unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments, which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial Intelligence/Digital Medicine.
50GF Score
Get the complete analysis for XSWX:XLS
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:XLS has been successfully added to your 
